-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on AtriCure, Raises Price Target to $63

Benzinga·10/12/2026 09:56:04
Diffusion vocale
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.